Gabriel Abreu

923 total citations
49 papers, 582 citations indexed

About

Gabriel Abreu is a scholar working on Rheumatology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Gabriel Abreu has authored 49 papers receiving a total of 582 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Rheumatology, 20 papers in Radiology, Nuclear Medicine and Imaging and 11 papers in Immunology. Recurrent topics in Gabriel Abreu's work include Systemic Lupus Erythematosus Research (29 papers), Monoclonal and Polyclonal Antibodies Research (20 papers) and Lymphoma Diagnosis and Treatment (9 papers). Gabriel Abreu is often cited by papers focused on Systemic Lupus Erythematosus Research (29 papers), Monoclonal and Polyclonal Antibodies Research (20 papers) and Lymphoma Diagnosis and Treatment (9 papers). Gabriel Abreu collaborates with scholars based in United States, Sweden and Australia. Gabriel Abreu's co-authors include Raj Tummala, Richard Furie, Eric F. Morand, Rubana N. Kalyani, Ian N Bruce, Lilia Pineda, Kenneth Kalunian, Susan Manzi, Yoshiya Tanaka and Joan T. Merrill and has published in prestigious journals such as SHILAP Revista de lepidopterología, Hypertension and Annals of the Rheumatic Diseases.

In The Last Decade

Gabriel Abreu

43 papers receiving 570 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gabriel Abreu United States	11	449	282	217	96	68	49	582
M.T. Guinnepain France	11	223 0.5×	122 0.4×	67 0.3×	13 0.1×	121 1.8×	34	776
Mitsuhiko Nambu Japan	12	80 0.2×	165 0.6×	37 0.2×	30 0.3×	32 0.5×	44	576
Samuel García‐Arellano Mexico	14	75 0.2×	133 0.5×	16 0.1×	40 0.4×	44 0.6×	30	356
Daniel Radoux Belgium	13	38 0.1×	346 1.2×	73 0.3×	67 0.7×	55 0.8×	19	619
Elizabeth Lee United States	8	34 0.1×	115 0.4×	103 0.5×	44 0.5×	159 2.3×	12	530
M Andary France	10	76 0.2×	247 0.9×	52 0.2×	21 0.2×	36 0.5×	21	493
Enriqué Raya-Álvarez Spain	9	61 0.1×	74 0.3×	22 0.1×	49 0.5×	42 0.6×	22	275
C. Pickard United Kingdom	10	109 0.2×	225 0.8×	12 0.1×	48 0.5×	92 1.4×	15	589
Kenan Aydoğan Türkiye	11	121 0.3×	74 0.3×	14 0.1×	31 0.3×	86 1.3×	36	356
Majid Zeidi United States	10	139 0.3×	121 0.4×	13 0.1×	18 0.2×	30 0.4×	21	368

Countries citing papers authored by Gabriel Abreu

Since Specialization

Citations

This map shows the geographic impact of Gabriel Abreu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gabriel Abreu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gabriel Abreu more than expected).

Fields of papers citing papers by Gabriel Abreu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gabriel Abreu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gabriel Abreu. The network helps show where Gabriel Abreu may publish in the future.

Co-authorship network of co-authors of Gabriel Abreu

This figure shows the co-authorship network connecting the top 25 collaborators of Gabriel Abreu. A scholar is included among the top collaborators of Gabriel Abreu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gabriel Abreu. Gabriel Abreu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tanaka, Yoshiya, Tatsuya Atsumi, Masato Okada, et al.. (2025). Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trial. Modern Rheumatology. 35(3). 458–469. 1 indexed citations

Tanaka, Yoshiya, Tatsuya Atsumi, Tomoya Miyamura, et al.. (2025). Disease activity and glucocorticoid tapering patterns in Japanese patients with systemic lupus erythematosus treated with anifrolumab: Post hoc analysis of the Japanese subpopulation of the TULIP-2 study. Modern Rheumatology. 35(3). 470–477. 1 indexed citations

Morand, Eric F., Ronald van Vollenhoven, Richard Furie, et al.. (2025). LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials. Annals of the Rheumatic Diseases. 84(5). 777–788. 4 indexed citations

Strand, Vibeke, Kenneth Kalunian, Gabriel Abreu, et al.. (2025). Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial. The Lancet Rheumatology. 7(7). e485–e494. 2 indexed citations

Touma, Zahi, Ian N Bruce, Richard Furie, et al.. (2025). Reduced organ damage accumulation in adult patients with SLE on anifrolumab plus standard of care compared to real-world external controls. Annals of the Rheumatic Diseases. 84(5). 767–776. 1 indexed citations

Abreu, Gabriel, et al.. (2024). Fluoxetine alters rat's milk properties causing impact on offspring's development. Toxicology and Applied Pharmacology. 483. 116805–116805.

Vollenhoven, Ronald van, Eric F. Morand, Richard Furie, et al.. (2024). LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis. SHILAP Revista de lepidopterología. A169–A170. 2 indexed citations

Abreu, Gabriel, et al.. (2024). Peripubertal exposure of atrazine cause decrease in exploratory activity, deficits in sociability and few alterations on brain monoaminergic systems of rats. Toxicology and Applied Pharmacology. 483. 116819–116819. 3 indexed citations

Morand, Eric F., Ronald van Vollenhoven, Richard Furie, et al.. (2023). OP0051 LUPUS LOW DISEASE ACTIVITY STATE ATTAINMENT IN THE PHASE 3 PLACEBO-CONTROLLED TULIP LONG-TERM EXTENSION TRIAL OF ANIFROLUMAB. Annals of the Rheumatic Diseases. 82. 33–34. 5 indexed citations

10.

Morand, Eric F., Gabriel Abreu, Richard Furie, Vera Golder, & Raj Tummala. (2023). Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Annals of the Rheumatic Diseases. 82(5). 639–645. 36 indexed citations

11.

Vital, Edward M, Zahir Amoura, Kenneth Kalunian, et al.. (2023). AB0514 LABORATORY MARKER IMPROVEMENTS FOLLOWING LONG-TERM TREATMENT WITH ANIFROLUMAB IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE PLACEBO-CONTROLLED TULIP EXTENSION STUDY. Annals of the Rheumatic Diseases. 82. 1451–1452.

12.

Abreu, Gabriel, et al.. (2023). Ketamine causes poor maternal care in rats with postpartum depression and leads to few behavioral and neurochemical alterations on male offspring. Behavioural Brain Research. 459. 114799–114799. 2 indexed citations

13.

Bruce, Ian N, Ronald van Vollenhoven, Eric F. Morand, et al.. (2022). Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: apost hocanalysis of the TULIP-1 and TULIP-2 trials. Lara D. Veeken. 62(4). 1526–1534. 20 indexed citations

14.

Strand, Vibeke, Sean O’Quinn, Richard Furie, et al.. (2022). Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. The Lancet Rheumatology. 4(3). e198–e207. 12 indexed citations

15.

Vital, Edward M, Joan T. Merrill, Eric F. Morand, et al.. (2022). Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases. 81(7). 951–961. 79 indexed citations

16.

Kalunian, Kenneth, Richard Furie, Eric F. Morand, et al.. (2022). A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus. Arthritis & Rheumatology. 75(2). 253–265. 82 indexed citations

17.

Morand, Eric F., Richard Furie, Yoshiya Tanaka, et al.. (2021). POS0691 EFFECTS OF ANIFROLUMAB ON RENAL DISEASE IN PATIENTS WITH SLE. Annals of the Rheumatic Diseases. 80(Suppl 1). 592.2–593. 2 indexed citations

18.

Bruce, Ian N, M. Edward Pierson, Yen Lin Chia, et al.. (2020). Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Rheumatology. 3(2). e101–e110. 19 indexed citations

19.

Abreu, Gabriel, et al.. (2019). Exposure of dams to fluoxetine during lactation disturbs maternal behavior but had no effect on the offspring behavior. Behavioural Brain Research. 377. 112246–112246. 10 indexed citations

20.

Nicoletti, María Aparecida, et al.. (2018). Antioxidant Action of Rosemary and Oregano Extract in Pre-Cooked Meat Hamburger. Food and Nutrition Sciences. 9(7). 806–817. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact